Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia
because of their high clinical efficacy. However, SGA treatment is associated with severe …

Schizophrenia is a debilitating psychiatric disorder that is treated with antipsychotics.
However, despite their efficacy, antipsychotics increase the risk of metabolic disorders in a …

Purpose Obesity and insulin resistance are considered cardinal to the pathophysiology of
metabolic syndrome. Several simple indexes of insulin resistance calculated from …

Hypothalamic detection of elevated circulating glucose triggers suppression of endogenous
glucose production (EGP) to maintain glucose homeostasis. Antipsychotics alleviate …

The second generation antipsychotic drug clozapine represents the most effective
pharmacotherapy for treatment-resistant psychosis. It is also associated with low rates of …

Since the serendipitous discovery of the first antipsychotic (AP) drug in the 1950s, APs
remain the cornerstone of treatment for schizophrenia. A shift over the past two decades …

Introduction: Patients living with schizophrenia have a marked risk of clinically significant
weight gain and obesity compared to the general population. The risks have been …

Objective Although a relationship between schizophrenia (SCZ), antipsychotic (AP)
medication, and metabolic dysregulation is now well established, the effect of adiposity is …

Metabolic tests are vital to determine in vivo insulin sensitivity and glucose metabolism in
preclinical models, usually rodents. Such tests include glucose tolerance tests, insulin …

Antipsychotic (AP) medications are associated with an increased risk of developing
metabolic side effects including weight gain, type 2 diabetes (T2D), dyslipidemia, and …